Interleukin‐1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
It was hypothesized that IL‐1 antagonism would preserve β‐cell function in new onset Type 1 diabetes (T1D). However, the Anti‐Interleukin‐1 in Diabetes Action (AIDA) and TrialNet Canakinumab (TN‐14) trials failed to show efficacy of IL‐1 receptor antagonist (IL‐1Ra) or canakinumab, as measured by stimulated C‐peptide response. Additional measures are needed to define immune state changes associated with therapeutic responses. Here, we studied these trial participants with plasma‐induced transcriptional analysis. In blinded analyses, 70.2% of AIDA and 68.9% of TN‐14 participants were correctly called to their treatment arm. While the transcriptional signatures from the two trials were distinct, both therapies achieved varying immunomodulation consistent with IL‐1 inhibition. On average, IL‐1 antagonism resulted in modest normalization relative to healthy controls. At endpoint, signatures were quantified using a gene ontology‐based inflammatory index, and an inverse relationship was observed between measured inflammation and stimulated C‐peptide response in IL‐1Ra‐ and canakinumab‐treated patients. Cytokine neutralization studies showed that IL‐1α and IL‐1β additively contribute to the T1D inflammatory state. Finally, analyses of baseline signatures were indicative of later therapeutic response. Despite the absence of clinical efficacy by IL‐1 antagonist therapy, transcriptional analysis detected immunomodulation and may yield new insight when applied to other clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798
Self-citationGenesis: cluster analysis of microarray data
Sturn, A., Quackenbush, J., & Trajanoski, Z. (2002) · Bioinformatics · doi:10.1093/bioinformatics/18.1.207 · Cited by 1,761
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes
Keymeulen, B., Vandemeulebroucke, E., Ziegler, A. G., Mathieu, C., Kaufman, L., Hale, G., Gorus, F., Goldman, M., Walter, M., Candon, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043980 · Cited by 1,099
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function
Pescovitz, M. D., Greenbaum, C. J., Krause-Steinrauf, H., Becker, D. J., Gitelman, S. E., Goland, R., Gottlieb, P. A., Marks, J. B., McGee, P. F., Moran, A. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904452 · Cited by 1,093
Self-citationOrjalo, A. V., Bhaumik, D., Gengler, B. K., Scott, G. K., & Campisi, J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905299106 · Cited by 654
Todd, J. A. (2010) · Immunity · doi:10.1016/j.immuni.2010.04.001 · Cited by 560
Sherry, N., Hagopian, W., Ludvigsson, J., Jain, S. M., Wahlen, J., Ferry, R. J., Bode, B., Aronoff, S., Holland, C., Carlin, D., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60931-8 · Cited by 493
Fall in C-Peptide During First 2 Years From Diagnosis
Greenbaum, C. J., Beam, C. A., Boulware, D., Gitelman, S. E., Gottlieb, P. A., Herold, K. C., Lachin, J. M., McGee, P., Palmer, J. P., Pescovitz, M. D., et al. (2012) · Diabetes · doi:10.2337/db11-1538 · Cited by 319
Self-citationKLF4 regulates the expression of interleukin-10 in RAW264.7 macrophages
Liu, J., Zhang, H., Liu, Y., Wang, K., Feng, Y., Liu, M., & Xiao, X. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.07.157 · Cited by 49
Cited by
The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives
Tsalamandris, S., Antonopoulos, A. S., Oikonomou, E., Papamikroulis, G.-A., Vogiatzi, G., Papaioannou, S., Deftereos, S., & Tousoulis, D. (2019) · European Cardiology Review · doi:10.15420/ecr.2018.33.1 · Cited by 1,381
Muscle–Organ Crosstalk: The Emerging Roles of Myokines
Severinsen, M. C. K., & Pedersen, B. K. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa016 · Cited by 1,226
Anti-inflammatory effects of exercise: role in diabetes and cardiovascular disease
Pedersen, B. K. (2017) · European Journal of Clinical Investigation · doi:10.1111/eci.12781 · Cited by 617
Targeting innate immune mediators in type 1 and type 2 diabetes
Donath, M. Y., Dinarello, C. A., & Mandrup-Poulsen, T. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0213-9 · Cited by 416
Self-citationThe physiology of optimizing health with a focus on exercise as medicine
Pedersen, B. K. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020518-114339 · Cited by 163
Metadata
- Authors
- Cabrera, S. M., Wang, X., Chen, Y., Jia, S., Kaldunski, M. L., Greenbaum, C. J., the Type 1 Diabetes TrialNet Canakinumab Study Group, Mandrup‐Poulsen, T., the AIDA Study Group, & Hessner, M. J.
- Venue
- European Journal of Immunology
- Publisher
- Wiley
- Published
- 2016-01-21
- Volume
- 46
- Issue
- 4
- Pages
- 1030-1046
- ISSN
- 0014-2980 (ISSN-L)
- 1521-4141
- OpenAlex
- W2207297826
- Cited by
- 56
- References
- 9
- FWCI
- 4.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interleukin‐1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset. https://app.cochat.ai/papers/10.1002/eji.201546005
- The paper
- Cabrera, S. M., Wang, X., Chen, Y., Jia, S., Kaldunski, M. L., Greenbaum, C. J., the Type 1 Diabetes TrialNet Canakinumab Study Group, Mandrup‐Poulsen, T., the AIDA Study Group, & Hessner, M. J. (2016). Interleukin‐1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset. European Journal of Immunology. https://doi.org/10.1002/eji.201546005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.